FDA’s Combo Product GMP Reg Speeds Ahead Unchanged
This article was originally published in The Gold Sheet
Executive Summary
Agency decides to keep the proposed rule, issued in 2009, “largely identical” and denies requests to delay implementation a year.
You may also be interested in...
FDA Combination Products Office Finalizing Manufacturing, Adverse Event Rules
FDA's Office of Combination Products is also developing guidance on how to determine whether a medical product is a device, drug or biologic.
Company Questions Remain Unanswered In FDA's Combo Products GMP Rule
Agency's proposed "streamlined approach" to combination product manufacturing raises a number of practical questions, such as what elements are actual components of a combo product and at what stage the streamlined system kicks in, firms say.
Patient-Focused Drug Development, Complex Trial Design May Not Get More Funding In PDUFA VII
US FDA proposed increasing staffing and resources for both programs during the next user fee program cycle, but industry representatives did not believe it necessary.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: